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Background: Treatment of sickle cell anemia is a challenging task and despite the well
understood genetic and biochemical pathway of sickle hemoglobin, current therapy contin-
ues  to be limited to the symptomatic treatment of pain, supplemental oxygen, antibiotics,
red  blood cell transfusions and hydroxyurea. SANGUINATE is a carbon monoxide releasing
molecule and oxygen transfer agent under clinical development for the treatment of sickle
cell  anemia and comorbidities.
Methods: An open-label randomized Phase Ib study was performed in adult sickle cell ane-
mia  patients. Two dose levels of SANGUINATE were compared to hydroxyurea in 24 homozy-
gotes for Hb SS. Twelve subjects received either a low dose (160 mg/kg) of SANGUINATE or
15  mg/kg hydroxyurea. Another 12 subjects received either a high dose (320 mg/kg) of SAN-
GUINATE or 15 mg/kg hydroxyurea. The primary endpoint was the safety of SANGUINATE
versus hydroxyurea in sickle cell anemia patients. Secondary endpoints included determi-
nation of the plasma pharmacokinetics and assessment of hematologic measurements.
Results: Musculoskeletal related adverse events were the most common. Transient tro-
ponin I levels increased in three patients, one of whom had an increase in tricuspid
regurgitant velocity; however, no clinical signs were noted. Following an assessment of vital
signs, tricuspid regurgitant velocity, electrocardiogram, serum biochemistry, hematology,
urinalysis, and analysis of reported adverse events, SANGUINATE was found to be safe in
stable sickle cell anemia patients.
Conclusions: The clinical trial met its primary objective of demonstrating an acceptable
safety proﬁle for SANGUINATE in patients with sickle cell anemia. This trial established
the safety of SANGUINATE at both dose levels and permitted its advance to Phase II trials.Please cite this article in press as: Misra H, et al. A Phase Ib open label, ran
anemia. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.
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Introduction
Treatment of sickle cell anemia (SCA) is a challenging task and
there is only one drug, hydroxyurea, approved by the Food and
Drug Administration (FDA) of the United States. Pain is the
most frequent manifestation of SCA and is thought to be a
consequence of vaso-occlusion. Vaso-occlusive crises are the
primary cause of frequent hospitalization of SCA patients and
are a major cause of death in adult SCA patients.1,2 Despite the
well-understood genetic and biochemical pathway of sickle
hemoglobin and many  discoveries of biomarkers of sickle cell
pathophysiology, modern-day therapy continues to be limited
to symptomatic treatment of pain, supplemental oxygen,
antibiotics therapy, red blood cell transfusions, and hydrox-
yurea. SCA is an inherited blood disorder caused by a defective
hemoglobin protein. The polymerization of sickle hemoglobin
is associated with many  abnormal downstream processes, but
no single pathway has been shown to play a primary or critical
role in complications occurring in SCA patients. This cascade
of events is responsible for the development of comorbidities
associated with SCA such as vaso-occlusion, stroke, leg ulcers,
and acute chest syndrome.
SANGUINATE (pegylated bovine carboxyhemoglobin) rep-
resents a novel approach to treating acute exacerbations of
SCA by targeting the underlying inﬂammation and causes of
hypoxia. SANGUINATE is a carbon monoxide releasing/oxygen
transfer agent being developed for the treatment of anemic
and ischemic hypoxia that result from congenital or acquired
hemoglobinopathies and vasculopathies, such as SCA and
thalassemia, and from cerebrovascular or peripheral vascular
diseases.
As SANGUINATE contains a hemoglobin core, there are
particular concerns regarding potential vasoactivity. Trials
performed with previous hemoglobin-based oxygen carri-
ers reported adverse events such as hypertension, cardiac
arrhythmias/conduction disorders, gastrointestinal symp-
toms, abnormal liver function tests and hemorrhage/anemia.3
The underlying pathophysiological mechanisms for these
cardiac effects are not precisely known but they have
been attributed to the scavenging of nitric oxide.4 SAN-
GUINATE, due to the modiﬁcation by polyethylene glycol and
the anti-vasoconstrictive activity of carbon monoxide, has
demonstrated no vasoactivity in vivo.5 An ascending dose
study of three cohorts of eight healthy volunteers found no
serious adverse events at doses of 80, 120 or 160 mg/kg.6 This
Phase Ib trial revealed no serious treatment-related adverse
effects and showed dose-proportional pharmacokinetics. As
SCA patients suffer from inﬂammation and anemia, which
cause a number of comorbidities, an open label, randomized
Phase Ib trial was undertaken to ensure the safety of SAN-
GUINATE in clinically stable patients who  are homozygous for
SCA.
MethodsPlease cite this article in press as: Misra H, et al. A Phase Ib open label, ran
anemia. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh
This open label randomized Phase Ib trial was conducted
in two countries and four medical centers in Central and
South America. These studies were conducted in compliance
with the US Food and Drug Administration regulations. The 0 1 6;x  x x(x x):xxx–xxx
trial was registered as NCT01848925. Protocols were designed
together with the investigators. Approvals were granted by the
Ethics Committees and Regulatory Authorities. The authors
had access to primary clinical trial data.
Adult patients with conﬁrmed SCA were enrolled. Eligibility
criteria included age of 18 years or older, baseline hemoglobin
level >6 or <10 g/dL, taking hydroxyurea or not, but must have
been dose stabilized for at least three months and able to
discontinue hydroxyurea for seven days prior to randomiza-
tion. Female patients of childbearing age were required to
use a medically acceptable form of contraception during both
studies and negative serum pregnancy tests were required
at enrollment and prior to infusion. Patient exclusion crite-
ria included individuals on a chronic transfusion program
(deﬁned as regular transfusions every 2–8 weeks), acute chest
syndrome, serious infections, allergies to hydroxyurea, history
of clinically signiﬁcant diseases and electrocardiogram (ECG)
abnormalities. Moreover patients were excluded if they had
had more  than six Emergency Room visits/hospitalizations
per year for SCA-related pain events, renal or liver dysfunc-
tion, troponin I >0.31 ng/mL, amylase or lipase >1.1 × upper
limit of normal, treatment with investigational drug within 60
days or intention to begin new drug therapy during the study
period.
Preparation  and  dosing
SANGUINATETM (Prolong Pharmaceuticals, LLC, South Plain-
ﬁeld, New Jersey) 40 mg/mL  for intravenous infusion was
provided in 500 mL  ethylene vinyl acetate blood bags which
were shipped in heat-sealed Mylar, gas impermeable foil over-
pack bags containing an inert gas, which served to protect the
product. SANGUINATE was stored under secure conditions in a
locked, limited-access refrigerator, at 2–8 ◦C. Droxia® (hydrox-
yurea; Bristol Myers Squibb, Princeton NJ) as 100 mg  capsules
was obtained through a commercial pharmacy and provided
unaltered as per the product labeling.
Twenty-four adult SCA patients (Hb SS) were randomized
2:1 to receive, unblinded, either a single 2-h intravenous infu-
sion of SANGUINATE, or a standard dose of hydroxyurea
(HU) with 2 h at resting stage. The ﬁrst 12 patients were to
receive either 160 mg/kg of SANGUINATE (eight patients) or
15 mg/kg of hydroxyurea (four patients), and the second 12
patients were to receive either 320 mg/kg of SANGUINATE
(eight patients) or 15 mg/kg of hydroxyurea (four patients). The
overall study design is presented in Figure 1.
Safety  assessment
Safety was evaluated throughout the study by assessments
over a 7-day period. Patients remained in the study center for
a minimum of 48 h after the start of dosing to complete a series
of safety assessments including blood and urine lab tests, ECG,
and physical exam compared to pre-dosing baseline values. A
24-h urine collection was performed as a measure of dehydra-
tion. Urine was collected over 48 h and creatinine clearancedomized, safety study of SANGUINATETM in patients with sickle cell
.2016.08.004
was tested to assess kidney function every 24 h. Vital signs as
well as evaluations of signs or symptoms of adverse events
were conducted periodically by physical exam and patient
interview.
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patients
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All subjects
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2:1
Visit 1
Screen
(Day - 7)
Day of admission
(Day 0: includes
baseline labs+
treadmill/pain score)
Day after dosing
(Day 2: includes
spirometry/
treadmill/pain)
Inpatient
(Days 3: 
includes
spirometry
/pain)
Outpatient
follow-up
(Day 5)
Outpatient
follow-up
(Day 4)
Final
visit
(Day 7±1)
Day of dosing
(Day 1: includes predose
echo + troponin +
spirometry, and postdose
echos + treadmill/pain)
Visit 2 (Inpatients)
+ PK blood draws for patients reciving SANGUINATE
Visit 3 Visit 4 Visit 5
SANGUINATE 160 mg/kg
(8 patients)
Hydroxyurea 15 mg/kg
(4 patients)
SANGUINATE 320 mg/kg
(8 patients)
Hydroxyurea 15 mg/kg
(4 patients)
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harmacokinetic  assessment
lasma SANGUINATE concentrations were quantiﬁed using
 validated high performance liquid chromatography (HPLC)
ethod. Serial blood samples for pharmacokinetic analy-
is were collected at baseline and at 0.5, 1, 1.5, 2, 4, 6,
, 12, 24, 36, 48, 72 and 96 h from the start of infusion.
on-compartmental pharmacokinetic methods were used to
etermine the pharmacokinetic parameters, which included
aximum and minimum measured plasma concentration
Cmax and Cmin, respectively), time to reach maximum plasma
oncentration (tmax), the area under the plasma concentration
ersus time curve from time zero to the time of the last mea-
urable plasma concentration [area under curve (AUC) 0 → ],
rea under the plasma concentration versus time curve from
ime zero to Inﬁnity (AUC 0 → ∞),  terminal half-life (t1/2) and
he apparent elimination rate constant (z).
esults
emographics  and  disposition
verall, the majority of patients were female (15) and of
ace ‘other’ (23 reported as Hispanic/Latino, and Black or
ixed/multiracial). Patients in the 160 mg/kg SANGUINATE
reatment group were on average slightly younger than the
ther treatment groups, but this group also included the
ldest patient in the trial (54 years). There was no signif-
cant difference in average height and weight between the
ydroxyurea-treated and the SANGUINATE-treated patients.
here were no remarkable differences between treatment
roups in medical history and there were no unexpected ﬁnd-
ngs (not related to SCA) for any patient in the baseline physical
xamination.Please cite this article in press as: Misra H, et al. A Phase Ib open label, ran
anemia. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.
A total of 24 stable SCA patients from clinical centers in
olombia and Panama were enrolled. Of the 24 patients, 22
eceived their assigned study medication and completed the
tudy as per protocol. Fifteen patients received SANGUINATEstudy design.
and seven patients received hydroxyurea. Two patients dis-
continued before receiving medications.
Pharmacokinetics
The pharmacokinetics of SANGUINATE were dose-dependent.
The mean blood levels of SANGUINATE for the two dose groups
are shown in Figure 2. For patients receiving the 160 mg/kg
dose of SANGUINATE, the mean peak concentration (Cmax)
was 2.59 mg/mL  and the mean peak concentration with the
320 mg/kg dose was 6.46 mg/mL. Both maximums occurred
at 2 h (completion of the infusion). Doubling the dose from
160 mg/kg to 320 mg/kg led to a mean 150% increase in peak
blood level of SANGUINATE in this SCA patient population. In a
previous study of healthy subjects receiving a single infusion
of 160 mg/kg SANGUINATE, all of the six subjects had blood
levels below the level of detection at 96 h after the infusion.6
Safety
More  adverse experiences were reported in the SANGUINATE
groups than reported in the hydroxyurea groups. Of the 44
reported adverse events in SANGUINATE-treated patients,
16 were from only two of the 15 patients. In addition, 46
of the 51 reported adverse events involving pain (including
headache). Musculoskeletal and connective tissue disorder-
related adverse events were the most commonly reported,
with arthralgia accounting for ten (nine SANGUINATE, one
hydroxyurea) of the 51 reports (Table 1).
Mean increases in systolic and diastolic arterial blood
pressures (transient) were expected following SANGUINATE
infusions due to its plasma expansion properties in the blood-
stream. These increases do not appear to be dose-dependent.
The mean systolic blood pressure following infusion ofdomized, safety study of SANGUINATETM in patients with sickle cell
2016.08.004
320 mg/kg is not appreciably different from the 160 mg/kg
group (Figure 3). The chart of mean diastolic pressures
(Figure 4) supports the suggestion that the oncotic effect may
not be dose-dependent.
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Figure 2 – Mean plasma concentration of SANGUINATE (mg/mL) by dose.Many  of the laboratory parameters that were abnormal at
baseline remained outside of the normal range for the dura-
tion of the study, and for many  laboratory parameters, there
were no meaningful differences between treatment groups.
Mean values for hemoglobin and hematocrit over time showPlease cite this article in press as: Misra H, et al. A Phase Ib open label, ran
anemia. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh
that treatment with SANGUINATE does not provide an appre-
ciable increase in quantity or concentration of hemoglobin in
these patients.
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Figure 3 – Mean systolHowever, the levels of direct (conjugated) bilirubin (Table 2)
demonstrated a clear mean decrease on the day of dosing rela-
tive to baseline levels for the patients receiving SANGUINATE,
which was not seen in the hydroxyurea treatment group.
Notably, the mean level following infusion of 320 mg/kg SAN-domized, safety study of SANGUINATETM in patients with sickle cell
.2016.08.004
GUINATE approximates the upper limit of the laboratory’s
normal range. This mean treatment difference is not appar-
ent in the level of total bilirubin, but is closely mirrored, albeit
100 120 140 160
G160 SG320
ic blood pressure.
Please cite this article in press as: Misra H, et al. A Phase Ib open label, randomized, safety study of SANGUINATETM in patients with sickle cell
anemia. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.2016.08.004
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Table 1 – Summary of adverse events.
Body system Hydroxyurea Sanguinate Sanguinate
160 mg/kg 320 mg/kg
Cardiac disorders 0 0 1
Tricuspid valve incompetence 0 0 1
Ear and labyrinth disorders 0 1 0
Ear pain 0 1 0
Gastrointestinal disorders 0  1 4
Abdominal pain 0  0 2
Abdominal pain upper 0 0 1
Nausea 0 1 1
General disorders/administration site conditions 1 2 1
Chest pain 0 1 0
Feeling cold 0 0 1
Infusion site erythema 0 1 0
Non-cardiac chest pain 1 0 0
Infections and infestations 1 2 1
Inﬂuenza 0 2 0
Upper respiratory tract infection 0 0 1
Viral infection 1 0 0
Injury/procedural complications 0 1 0
Contusion 0 1 0
Investigations 1 0 1
Oxygen saturation decreased 1 0 0
Troponin I increased 0  0 1
Musculoskeletal/connective tissue disorders 3 10 9
Arthralgia 1 4 5
Back pain 1 1 0
Bone pain 0 0 1
Musculoskeletal chest pain 0 1 0
Musculoskeletal pain 0 1 2
Neck pain 0 0 1
Pain in extremity 1 3 0
Nervous system disorders 1 2 2
Dizziness 0 0 1
Headache 1 2 1
Respiratory, thoracic, mediastinal disorders 0 0 2
Pulmonary hypertension 0 0 1
Tachypnoea 0 0 1
Skin and subcutaneous tissue disorders 0 1 1
Erythema 0 1 0
Pruritus 0 0 1
Vascular disorders 0 1 1
Endothelial dysfunction 0 0 1
Orthostatic hypotension 0 1 0
Table 2 – Direct Bilirubin and gamma-glutamyl transpeptidase (GGT).
Units Statistic Hydoxyurea Sanguinate (160 mg/kg) Sanguinate (320 mg/kg)
Baseline
result
Visit
result
Difference Baseline
RESULT
Visit
result
Difference Baseline
result
Visit
result
Difference
Bilirubin mg/dL n  7 7 7 8 8 8 7 7 7
Mean 0.7 0.7 0 1.2 0.5 −0.7 0.7 0.2 −0.5
Std. dev. 0.2 0.2 0.1 0.7 0.4 0.3 0.2 0.1 0.1
Median 0.7 0.6 0 1.2 0.4 −0.7 0.6 0.2 −0.4
Minimum 0.3 0.5 −0.2 0.4 0.1 −1.2 0.5 0 −0.7
Maximum 1.1 1.2 0.2 2.6 1.4 −0.3 1 0.4 −0.3
GGT U/L n 7 7 7 8 8 8 7 7 7
Mean 41 40.4 −0.6 55.5 33.5 −22 49.1 26.6 −22.6
Std. dev. 29.3 30.4 1.9 53 40 16.5 46.1 36.3 11.9
Median 42 41 −1 35.5 22.5 −19 24 9 −17
Minimum 10 10 −3 22 3 −59 14 1 −42
Maximum 95 98 3 181 122 −4 141 99 −11
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olic Figure 4 – Diast
always within the normal range, in the levels of gamma-
glutamyl transpeptidase.
The mean results of the chemical urinalysis test for pres-
ence of blood in the urine show a treatment-speciﬁc (though
not apparently dose-speciﬁc) difference following infusion
with SANGUINATE. The mean red blood cell levels seen upon
microscopic analysis approximately mirror this ﬁnding, which
may be the result of the increased colloid-osmotic pres-
sure produced by the infusion, causing an increase in forced
glomerular ﬁltration. A similar result was seen for urinary pro-
tein.
There were brief but substantial increases in troponin I lev-
els in three patients receiving SANGUINATE (320 mg/kg) and in
one patient receiving HU. The increases were of short duration
and not accompanied by any clinically identiﬁed or patient
reported adverse experiences. One of the three patients with
elevated troponin levels also had a reported serious adverse
event due to an increase in tricuspid regurgitant velocity
(TRV) which was labeled as a sign of moderate pulmonary
hypertension; however, associated symptoms of pulmonary
hypertension were not present after angiography. The other
two patients had baseline values near or above the upper limit
of the laboratory reference range for troponin I (0.028 ng/mL).
The highest measured level was also the shortest lasting: the
serum troponin I level of one patient was assayed at nearly
16-times the upper limit at 1 h after the end of SANGUINATE
infusion. Yet, despite reading above the limit at baseline, tro-
ponin I was down to the low level of normal (0.007) by the
time of the next measurement 5 h later, where it remained for
the duration of the study. Because of the short duration, and
because it was not accompanied by any clinically-identiﬁed or
patient-reported adverse experiences, these were not reportedPlease cite this article in press as: Misra H, et al. A Phase Ib open label, ran
anemia. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh
by the investigators as serious adverse events. One patient
receiving hydroxyurea also had a brief increase in troponin
I level (0.045 ng/mL) above the upper limit of the laboratory
reference range at 72 h after dosing.blood pressure.
Discussion
The pathobiology of SCA is characterized by inﬂammation
and oxygen deprivation. While hydroxyurea therapy has
decreased the painful episodes of SCA, poor compliance and
non-response by a signiﬁcant proportion of SCA patients
results in the development of vaso-occlusive crises and other
acute comorbidities. SANGUINATE is a novel construct of
hemoglobin that contains carbon monoxide and pegylated
bovine carboxyhemoglobin. It has been shown to reduce
infarct volume in animal models7,8 and has been adminis-
tered under multiple emergency Investigational New Drugs
(eINDs).9,10 In vitro studies have demonstrated the ability of
SANGUINATE to return SCA blood cells to a more  normal
morphology11 and demonstrated the transfer of oxygen to
hypoxic cells.
This ﬁrst in-patients study assessed the safety-related
effects of SANGUINATE in SCA patients. Since only 15 patients
received SANGUINATE and seven patients received hydrox-
yurea, the size of the study population was too small to
allow a calculation of statistical signiﬁcance between treat-
ment groups. It was observed that many  of the laboratory
parameters being measured were abnormal at baseline in
this population as expected. The damage that has devel-
oped in these patients from a lifetime of hemolytic anemia
and ischemic hypoxia means that they present an extremely
diverse range of possible physiological responses that may be
undetectable using the parameters and methods of this study.
The decrease in bilirubin and gamma-glutamyl transpep-
tidase may be due to the impact of SANGUINATE upon the
red blood cell. SANGUINATE has been shown to ‘unsickle’ red
blood cells in SCA patients in vitro.12 The improvement in red
blood cell morphology and blood ﬂow parameters may reducedomized, safety study of SANGUINATETM in patients with sickle cell
.2016.08.004
hemolysis and thereby impact these biochemical parameters.
This hypothesis remains to be conﬁrmed in larger clinical
studies.
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The clinical signiﬁcance of the transient increases in tro-
onin I levels seen in some of these patients is also not
lear. The transient elevation of troponin I in three of 15 sub-
ects lasted a few hours or a few days, without sequelae or
epeated elevations. Current American College of Cardiology
oundation (ACCF)/American Heart association (AHA) guide-
ines do not deﬁne the duration of troponin elevation needed
o indicate pathology, and do not recommend their diagnos-
ic or prognostic use alone in heart failure.13 Furthermore,
s clariﬁed in the 2007 Joint European Society of Cardiology
ESC)/ACCF/AHA/World Heart Federation (WHF) report “Uni-
ersal Deﬁnition of Myocardial Infarction”, serial measures
f cardiac troponin after the onset of clinical symptoms are
eeded for diagnosis of cardiac ischemia.14 A rapid rise and
all of troponin I does not ﬁt the standard cardiac disease
aradigm, and the return of troponin I levels to normal is
ndicative of response to treatment or spontaneous improve-
ent.
The response of one patient, who received 320 mg/kg SAN-
UINATE, of multi-day increases in TRV to levels typically
ssociated with moderate-to-severe pulmonary hypertension,
ubstantial increases in systemic blood pressure, and elevated
roponin I to nearly 4-fold the upper level of normal, lasting
everal days, are results which, albeit paradoxical, were associ-
ted with no clinically-identiﬁed or patient-reported adverse
ffects. Pulmonary hypertension, deﬁned by persistent TRV
alues above 3.0 m/s, has been correlated with a signiﬁcant
ncreased risk of mortality in SCA patients.15 The impact of
RV elevations above 3.0 m/s  that last for only a few days,
owever, occurring in SCA patients with average TRV levels
2.0 m/s  has not been determined. Given the lack of clinical
dverse effects of the patient, her professed well-being, and
he isolated nature of this event, the impact of the reported
vent on the understanding of risk related to the study drug
n SCA patients is very limited.
Infusion of SANGUINATE at both 160 and 320 mg/kg gen-
rated an expected increase in arterial pressure due to its
olloid osmotic properties, which resolved without appar-
nt sequelae. Mean systolic and diastolic systemic arterial
ressure was increased in SANGUINATE-treated patients com-
ared to hydroxyurea-treated patients, but accompanying
ean increases in TRV values were not seen in this study.
he known transient effect of SANGUINATE on arterial pres-
ure, possibly including pulmonary arterial pressure that was
ndetectable in this small study, is believed to be due solely
o its oncotic effect. The lack of clinically meaningful adverse
ffects resulting from the pressure increase further supports
 transient ﬂuid-volume basis for the mechanism.
Pharmacokinetic results found that SANGUINATE
160 mg/kg) had a prolonged T1/2 in stable SCA patients
19.56 h) compared to that found in healthy volunteers
13.75 h).7 In the Phase I study with healthy volunteers, it was
bserved that haptoglobin levels were signiﬁcantly reduced
ollowing SANGUINATE administration. Because the core of
ANGUINATE is hemoglobin, it has been proposed that the
learance mechanism will be the same as the mechanismPlease cite this article in press as: Misra H, et al. A Phase Ib open label, ran
anemia. Rev Bras Hematol Hemoter. 2016. http://dx.doi.org/10.1016/j.bjhh.
sed to clear native hemoglobin following hemolysis by
he reticuloendothelial system. Because of the widespread
emolysis in SCA patients, this clearance mechanism would
e burdened by the patient’s extensive cell-free hemoglobin, 1 6;x x x(x x):xxx–xxx 7
thus reducing the rate at which this mechanism can clear
SANGUINATE, which would lead to a longer circulatory
half-life.
Conclusion
This is a ﬁrst in-patient study of patients with stable SCA with
either 160 mg/kg or 320 mg/kg of SANGUINATE. While there
were more  adverse events in the SANGUINATE arm, they were
mild and self-limited. Following assessment of vital signs,
echocardiographic measures of TRV, electrocardiogram anal-
ysis, laboratory measures of serum biochemistry, hematology
and urinalysis, and reported adverse events, no clear evidence
of clinically meaningful safety concerns were identiﬁed. These
results support further development of SANGUINATE for the
treatment of SCA comorbidities and initiation of further clin-
ical trials designed to optimize dosing and select appropriate
endpoints to assess safety and efﬁcacy.
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